Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Esophageal Squamous Cell Carcinoma 6Triple Negative Breast Neoplasms 3Neoplasms 3Head and Neck Neoplasms 3Breast Neoplasms 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Lung Neoplasms 2Uterine Cervical Neoplasms 1Thymoma 1Thymic epithelial tumor 1Squamous NSCLC 1Small Cell Lung Carcinoma 1Salivary Gland Malignant Neoplasms 1Pathologic Complete Response 1Pancreatic cancer, adult 1Pancreatic Cancer Resectable 1Melanoma 1Mediastinal Neoplasms 1Locally Advanced Non-Small Cell Lung Cancer 1Gastric Adenocarcinoma 1Fallopian Tube Neoplasms 1Esophageal Squamous Carcinoma 1Carcinoma 1Brain Neoplasms 1Anophthalmia with pulmonary hypoplasia 1Advanced Triple Negative Breast Cancer 1

Interventions

pembrolizumab 1lenvatinib 1Paclitaxel 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Advanced Non-squamous Non-small-cell Lung Cancer × 130-nm albumin-bound paclitaxel × Clear all
NCT06028633 2023-09-13

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Peking University First Hospital

Phase 2 Not yet recruiting
28 enrolled
Thoracic

Advanced Non-squamous Non-small-cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡